Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab transcriptomic predictor study in moderately to severely active ulcerative colitis
2013-002042-36Phase 2Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golimumab in autoimmune colitis, sponsored by Janssen Biologics B.V. Primary endpoint: AUCROC of a subset of the length-109 probe set panel in predicting mucosal healing. Started Feb 2014; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-002042-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002042-36.